Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease.

Authors

Amer Beitinjaneh, University of Texas MD Anderson Cancer Center
Rima M. Saliba, University of Texas MD Anderson Cancer Center
L. Jeffrey Medeiros, University of Texas MD Anderson Cancer Center
Francesco Turturro, University of Texas MD Anderson Cancer Center
Gabriela Rondon, University of Texas MD Anderson Cancer Center
Martin Korbling, University of Texas MD Anderson Cancer Center
Luis Fayad, University of Texas MD Anderson Cancer Center
Michelle A. Fanale, University of Texas MD Anderson Cancer CenterFollow
Amin M. Alousi, University of Texas MD Anderson Cancer CenterFollow
Paolo Anderlini, University of Texas MD Anderson Cancer Center
Oran Betul, University of Texas MD Anderson Cancer Center
Uday R. Popat, University of Texas MD Anderson Cancer Center
Barbara Pro, Thomas Jefferson UniversityFollow
Issa F. Khouri, University of Texas MD Anderson Cancer Center

Document Type

Article

Presentation Date

5-1-2015

Comments

This article has been peer reviewed. It is the authors' final version prior to publication in Biology of Blood and Marrow Transplantation, Volume 21, Issue 5, May 2015, Pages 855-859.

The published version is available at DOI: 10.1016/j.bbmt.2015.01.013. Copyright © Elsevier Inc.

Abstract

We studied the roles of autologous (A) and allogeneic (allo) stem cell transplantation (SCT) in the treatment of 134 patients with T cell lymphoma (TCL) at our center. For frontline SCT, 58 patients were studied. The 4-year overall survival (OS) rates for ASCT (n = 47; median age, 49 years) and alloSCT (n = 11; median age, 55 years) groups were 76% and 54%, respectively (P > .05). The 4-year OS rates for first complete remission (CR1) patients were 84% and 83%, respectively. For SCT for relapsed disease, 76 patients were studied (41 with ASCT and 35 with alloSCT). The 4-year OS rates were 50% and 36% for ASCT and alloSCT patients with chemosensitive disease, respectively (P > .05). Those who were in CR2 and CR3 had 4-year OS rates of 59% and 53%, respectively. Similar results were also observed in patients with refractory disease (29% and 35%, respectively). These data suggest that a pre-SCT CR is associated with improved outcomes in TCL patients after SCT. Considering the 84% 4-year OS rates in CR1 patients and the unpredictable responses in patients with relapsed disease, we favor the use of ASCT as consolidation therapy after CR1. AlloSCT did not result in a superior outcome compared with ASCT.

Recommended Citation

Beitinjaneh, Amer; Saliba, Rima M.; Medeiros, L. Jeffrey; Turturro, Francesco; Rondon, Gabriela; Korbling, Martin; Fayad, Luis; Fanale, Michelle A.; Alousi, Amin M.; Anderlini, Paolo; Betul, Oran; Popat, Uday R.; Pro, Barbara; and Khouri, Issa F., "Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease." (2015). Kimmel Cancer Center Papers, Presentations, and Grand Rounds. Paper 33.
https://jdc.jefferson.edu/kimmelgrandrounds/33